Table 1

Epidemiological input data used in the modela
Gender Cancer sites (ICD 10 code) Expected number of new cases, irrespective of HPV status HPV prevalence by site (%) Expected number of new cases attributable to HPV Prevalence of HPV 16/18 in HPV-positive cancers (%) Expected number of new cancer cases attributable to HPV 16/18 Prevalence of HPV 6/11 in HPV-positive warts (%) Expected number of new cancer cases attributable to HPV 6/11
Male Head and neckb 67,354 14,098 12,707
Anus (C21) 2,162 84.2 1,821 87.1/6.2 1,699
Penis (C60) 3,178 46.7 1,484 60.2/13.4 1,091
Genital warts 380,961 85.5 325,722
Female Cervical cancer 30,517 - - 59.2/17.0 23,254
Vaginal 1,869 69.9 1,306 76.8/10.9 1,146
Vulvar 7,384 40.4 2,983 79.7/10.9 2,702
Anus (C21) 3,727 84.3 3,141 87.1/6.2 2,929
Head and neck 13,448 2,715 2,531
Genital warts 337,963 85.5 288,959

HPV, human papillomavirus.

aIn total 26 countries were considered in the analysis for incidence estimates, i.e. all European Union countries (except Greece, Hungary, Luxembourg, and Romania). Three countries outside the European Union were included (Iceland, Norway and Switzerland).

bincludes several ICD 10 codes related sites (i.e., tongue, gum of the mouth, floor of the mouth, palate, tonsil, piriform sinus), hypopharynx and larynx sites.

Marty et al.

Marty et al. BMC Cancer 2013 13:10   doi:10.1186/1471-2407-13-10

Open Data